Nachrichten zur ASTRAZENECA PLC DL-,25 Aktie

AstraZeneca investing $50B in US, Trump calls it an ‘honor’

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some…

Why is AstraZeneca is Investing $50bn into the US?

AstraZeneca is investing heavily in US facilities to counteract tariff impacts, planning substantial growth through local manufacturing by 2030…

AstraZeneca to invest $50B in US to boost drug manufacturing and R&D

AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant’s…

AstraZeneca announces $50 billion US investment in manufacturing and R&D By Investing.com

AstraZeneca announces $50 billion US investment in manufacturing and R&D…

AstraZeneca plant Mega-Investition in den USA: 50 Mrd. USD bis 2030

AstraZeneca hat angekündigt, bis 2030 50 Mrd. USD in den USA zu investieren. Damit ist es der jüngste Pharmakonzern, der…

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom…

AstraZeneca announces $50 billion U.S. investment

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing site in Virginia.…

Pharmaindustrie: AstraZeneca investiert 50 Milliarden Dollar in US-Produktion

Der schwedisch-britische Pharmakonzern AstraZeneca kündigt Milliarden-Investitionen in den USA an – und macht dabei kein Geheimnis daraus, dass Zeitpunkt und…

AstraZeneca plans to invest $50B in U.S. by 2030

…

AstraZeneca unveils $50 billion US investment as pharma tariff threat looms

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on…

AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers

AstraZeneca announces largest ever investment in U.S. manufacturing…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.…

AstraZenecas AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZNs anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.…

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study By Reuters

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study…

AstraZeneca drug fails main goal of late-stage amyloidosis study

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for…

UBS stuft ASTRAZENECA auf Buy

ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat Astrazeneca auf "Buy" mit einem Kursziel von 14200 Pence belassen. In…

ANALYSE-FLASH: JPMorgan lässt Astrazeneca auf 'Overweight' - Studiendaten

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca nach positiven Phase-III-Studiendaten…

AKTIE IM FOKUS: Daten zu Baxdrostat helfen AstraZeneca aufwärts

LONDON (dpa-AFX Broker) - Positive Studiendaten zu einem Medikament von Astrazeneca sind am Montag an der Londoner Börse gut…

AKTIE IM FOKUS: Daten zu Baxdrostat helfen AstraZeneca aufwärts

LONDON (dpa-AFX Broker) - Positive Studiendaten zu einem Medikament von Astrazeneca sind am Montag an…

AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead

Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts…

KORREKTUR/ANALYSE-FLASH: Berenberg hebt Ziel für Astrazeneca auf 14200 Pence

(Korrigiert wird das Kursziel. Es lautet 14200 rpt. 14200 Pence) HAMBURG (dpa-AFX Broker)…

AZNs Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.…

AstraZeneca-Aktie: AstraZeneca verhandelt Milliardendeal mit Summit Therapeutics

Der britische Pharmakonzern spreche derzeit mit Summit Therapeutics über eine Vereinbarung, in deren Rahmen AstraZeneca über mehrere Jahre bis zu…

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday,…

GOLDMAN SACHS stuft ASTRAZENECA auf Buy

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Astrazeneca von 14524 auf 14806 Pence angehoben…

What If London Loses One Of Its Top Companies?

Suggestions that AstraZeneca might cross the Atlantic should act as a huge wake-up call.…

London stock market could weather its biggest blow yet if AstraZeneca exits

AstraZeneca is the most valuable company listed on London’s FTSE 100 index.…

London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca…

Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors

Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last…

Why AstraZeneca Stock Topped the Market on Tuesday

Trading in AstraZenecas (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to…

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile…

AstraZeneca ‘may quit London stock market’

Pharma giant’s chief discusses shifting listing to US in potential blow to UK capital…

AstraZeneca reports total voting rights at over 1.55 billion shares By Investing.com

AstraZeneca reports total voting rights at over 1.55 billion shares…

AstraZeneca CEO eyes US market listing, The Times reports

AstraZeneca chief executive Pascal Soriot is considering moving the companys stock market listing to the United States, The Times reported…

AstraZeneca CEO wants to move Britain’s most valuable company to US

Sir Pascal Soriot is frustrated with restrictions on medicines by Nice and pricing under an NHS rebate scheme…

AstraZeneca: Navigating Challenges Across Geographies Well

…

IEFA Is a Great Choice for Most, but I Like VEA ETF Better

For investors in the United States, its pretty easy to get overexposed to domestic stocks. These are the brands that…

EQS-News: Attraktive Investmentperspektive: AstraZeneca zeigt Interesse an KI-Onkologie-Konsortium "PROmAI" (deutsch)

Attraktive Investmentperspektive: AstraZeneca zeigt Interesse an KI-Onkologie-Konsortium "PROmAI"^EQS-Media / 28.06.2025 / 14:56 CET/CESTOnco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco…

3 No-Brainer Stocks to Buy for Under $100 Right Now

Whats the biggest misconception about investing? The idea that you need a lot of money to get started is certainly…

EQS-News: Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-Konsortium (deutsch)

Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-Konsortium^Emittent / Herausgeber: MCS Market…

Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-Konsortium

Vancouver, Kanada - 27. Juni 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder…

IRW-News: Onco-Innovations Limited: Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-Konsortium

IRW-PRESS: Onco-Innovations Limited: Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-KonsortiumVancouver, Kanada…

Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…

FDA Grants Label Expansion to AstraZenecas Datroway in Lung Cancer

FDA expands AstraZenecas Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.…

ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem…

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire

If youre looking for stocks that have the potential to make you a millionaire on a relatively modest investment, youre…

Targeted cancer drugs may replace chemo for some patients — and drugmakers say theyre getting closer

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) concluded the recent trading session at $73.55, signifying a -1.17% move from its prior days close.…